Twitter/X

Intercept is a $500M philanthropic initiative launched by Nan Ransohoff to make…

2026-06-24 · 16:29 UTC ·@_sholtodouglas ·2 min read

Brief

Intercept, a $500M philanthropic initiative led by Nan Ransohoff, aims to eliminate common respiratory infections by funding development of broad‑spectrum preventatives and air‑cleaning technologies. The program will make equity investments to push candidates to Phase 2 within four years, fund basic‑research grants, validate far‑UVC and other air cleaners, and is backed by Stripe, Anthropic, The Flu Lab, Foundation OAI and Jane Street donors.

Why it matters

Intercept is a $500M philanthropic initiative launched by Nan Ransohoff to make respiratory infections 'a thing of the past'; anchor funders include Stripe, Anthropic, The Flu Lab, Foundation OAI, and individual donors from Jane Street.

Key details

  • Intercept will invest equity in broad‑spectrum preventatives targeted to reach Phase 2 within 4 years, award grants for basic research not yet commercially viable, and fund validation/deployment of air‑cleaning technologies (e.g., far‑UVC) for schools and workplaces.
  • Rationale: respiratory viruses cause ~1 million deaths per year, cost ~$600 billion annually in lost productivity, and keep people sick roughly 5% of their lives; Intercept convened ~40 scientists, pharma R&D leaders, investors, and regulators and identified technical complexity and chronic underfunding as the main barriers.
Source evidence

I (and a bunch of my colleagues) donated to this. I think it is a really excellent initiative. TLDR:
- Equity investments in broad spectrum preventatives that are ready to get to phase 2 within 4 years
- Grants for basic research that isn't yet ready for commercial viability
- Prove out air cleaning tech (like far-uvc), and make it extremely obvious whether it should be adopted in schools, workplaces etc.

Nan Ransohoff (@nanransohoff)

Today we're launching Intercept: a $500M philanthropic initiative to make respiratory infections, like the common cold and flu, a thing of the past.

We treat respiratory infections as a minor nuisance, but that’s really not the case. Most of us will spend 5% of our lives (!) sick from these viruses, they kill 1M people a year, cost $600B annually in productivity, and periodically threaten civilization through pandemics.

So, if they’re such a big problem, why haven’t we dealt with them yet? Last year we convened ~40 leading scientists, pharma R&D leaders, biotech investors, and regulatory experts to better understand that.

We heard two main reasons:
(1) First, it’s just technically very challenging: respiratory viruses represent hundreds of distinct, mutating strains across several families. Fortunately, recent breakthroughs make this newly possible.
(2) Second is a lack of funding: broad-spectrum solutions have historically been underfunded, in part because they’re not a great fit for most philanthropic or commercial funding (and while COVID generated a burst of activity around preventing and understanding respiratory infections through an influx of new funding, that hasn't been sustained).

We think that with enough focus and funding, this might be solvable. Intercept is a $500 million philanthropic initiative that will take advantage of new tools to catalyze the development and deployment of two types of products: broad-spectrum preventatives and air cleaning technologies.

This problem is undoubtedly difficult. But it’s more tractable now than it’s ever been. We think we should give it our best shot.

We’re enormously grateful to our anchor funders: @stripe, @AnthropicAI, @TheFluLab, @FoundationOAI and individuals from Jane Street.

And, I’m very excited to be building this with @incredutility and the rest of the team.

— https://nitter.net/nanransohoff/status/2069761661456601188#m